AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894
CRN04894-09
Phase 2 other active
Quick answer
AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894 for CONGENITAL ADRENAL HYPERPLASIA is a Phase 2 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- CONGENITAL ADRENAL HYPERPLASIA
- Phase
- Phase 2
- Modality
- other
- Status
- active